The human platelet alloantigens, pjAI and pjA2, comprise a diallelic antigen system located on a component of the platelet fibrinogen receptor, membrane glycoprotein (GP) MIIa. Of the known platelet alloantigens, pIA1 which is carried by 98% of the caucasian population, appears to be the alloantigen that most often provokes neonatal alloimmune thrombocytopenic purpura and posttransfusion purpura. The structural features of the GPIIIa molecule responsible for its antigenicity are as yet unknown. Using the polymerase chain reaction (PcR), we amplified the NH2-terminal region of platelet GPIIIa mRNA derived from PjAe and pIA2 homozygous individuals. Nucleotide sequence analysis of selected amplified cDNA products revealed a C * T polymorphism at base 196 that created a unique Nci I restriction enzyme cleavage site in the p1A2, but not the P1Ae form of GPIIIa cDNA. Subsequent restriction enzyme analysis of cDNAs generated by PcR from 10 p1Al/A1 5 P and 3 p1Al/AZ individuals showed that Nci I digestion permitted clear discrimination between the pIA1 and pIA2 alleles of GPIIIa. All pIA2/A2 individuals studied contain a C at base 196, whereas PIAl homozygotes have a T at this position.
Introduction
The human platelet membrane glycoprotein (GP)' Ilb-Illa complex mediates platelet aggregation by acting as the func-1. Abbreviations used in this paper: GP, glycoprotein; HEL, human erythroleukemia; NATP, neonatal alloimmune thrombocytopenic purpura; PcR, polymerase chain reaction; PTP, posttransfusion purpura.
tional receptor for fibrinogen on the platelet surface (1) . In addition to this physiological role, both GPIIb and GPIIIa are known to bear a number of clinically important alloantigenic determinants that are responsible for eliciting the immune response in two well-described clinical syndromes, postransfusion purpura (PTP) and neonatal alloimmune thrombocytopenic purpura (NATP) (2, 3) . The alloantigen system most frequently implicated in these disorders is P1A. There are two serologically defined allelic forms of the pIA alloantigen, PIl" and p1A2, both of which have been localized to the GPIIIa molecule (2) . The gene frequencies for these two alleles have been calculated to be 85% A1:15% A2 (4), based upon the observation that p1A2 homozygous individuals represent only 2% of the caucasian population. Since 98% of the population carries the PIA" antigen, p1A2 homozygotes are at risk of producing anti-PlAI antibodies against paternally inherited P1AI antigens present on fetal platelets, and are most likely to develop PTP after blood transfusion.
Molecular definition of platelet alloantigenic determinants would contribute significantly to the understanding of the morphological features of platelet membrane glycoproteins that are responsible for eliciting an alloimmune response. Carbohydrate residues have been shown not to contribute significantly to the formation of the immunogenic PIAl determinant (5) , but determination of the amino acid sequence variation(s) that are presumably responsible for forming the relevant epitopes has not yet been possible, due largely to the formidable task of obtaining protein sequence information of both pJAl and P1A2 forms of the I00-kD GPIIIa molecule. The complete amino acid sequence of GPIIIa has recently been deduced from the nucleotide sequences of both endothelial cell (6) and human erythroleukemia (HEL) cell (7, 8) GPIIIa cDNA clones, however it is likely that each of these clones represent the pIAl rather than the p1A2 allele, owing to the relative abundance of p1AI in the human gene pool.
Recently, we descril/ed a new approach for examining platelet-specific mRNA sequences from single individuals (9) . We demonstrated that the RNA derived from the platelets present in 50 ml of whole blood can be converted to cDNA and then enzymatically amplified using the polymerase chain reaction (PcR) to produce microgram quantities of plateletspecific cDNA. By isolating and amplifying mRNA from a number of individuals of known plA allotype, it should be possible to examine whether phenotype-specific nucleotide sequence variations exist in the GPIIIa gene. In this report, we present the first molecular description of a polymorphism associated with a human platelet alloantigen, and show that the pJAl allele can be distinguished from p1A2 by differential restriction endonuclease digestion of amplified platelet mRNA.
Methods
Serological determination ofPi' phenotype. The pIA phenotype of 18 different individuals was determined using a standard antigen-capture ELISA assay (10, 1 1). 10 homozygous PI" individuals, 5 homozygous PIA2 individuals, and 3 heterozygotes for the pIA allotype, all of whom had been unambiguously identified using well-characterized anti-PI"A and anti-PIA2 antisera, were used throughout this study.
Amplification ofplatelet mRNA. Human platelet mRNA was prepared from anticoagulated whole blood as described previously (9) . Two pairs ofprimers were constructed; an outer pair (primers 1 and 3), and an internally nested pair (primers 2 and 4), and used to amplify a region ofthe GPIIIa mRNA molecule that encodes the amino terminal 103 amino acids of mature glycoprotein IIa. Bases (6) . Primer 2 (5'-GACTCGAGACTGTGCTGG-CGCTG-3) corresponds to bases 56-71 of the RNA strand, with an additional 7 bases encompassing an Xho I restriction enzyme recognition site incorporated onto the 5'-end to facilitate subsequent subcloning into plasmid vectors. The two anti-sense oligonucleotides were primer 3 (5'-CGCACTTGGATGGAGAAATTC-3'), which corresponds to nucleotides 412-392, and primer 4 (5'-CCGGATCClTG-GATGGAGAAATTC-39, which corresponds to bases 408-392 plus an additional 7 bases that contain a Bam HI site. Primer 3 was used to prime first strand cDNA synthesis, using platelet mRNA as a template, in a total volume of 50 ,d as previously described (9) . All ensuing PcR reactions were performed in a programmable DNA thermal cycler (Perkin-Elmer Cetus Corp., Norwalk, CT). The first 10 rounds of PcR were performed using primers 1 and 3 in a total volume of 100 1 using a regimen consisting of denaturing nucleic acid strands at 94°C for 90 s, annealing primers at 37°C for 2 min, and primer extending with Taq polymerase (Perkin-Elmer Cetus Corp.) at 72°C for 3.5 min. After the fifth thermal cycle, the primer annealing temperature was increased to 42°C. After the tenth cycle, the first primer pair was removed by centrifuge-driven dialysis of the PcR reaction mixture into a nearly identical buffer using Centricon 30 microconcentrators (Amicon Corp., Danvers, MA). The second reaction mix was identical to the first, except that internally nested primers 2 and 4 were used in place of primers 1 and 3. After oligonucleotide exchange, the reaction volume was again brought to 100 ,l, including 2.5 U of fresh Taq polymerase, and PcR continued for an additional 21 thermal cycles. Primer annealing was performed at 42°C for rounds 11-15; 47°C for rounds 16-20, and 55°C for rounds 21-31. We have found that these conditions maximize specificity and yield for amplification of cDNA (unpublished observations). The presence of the additional bases used to form the restriction enzyme sites at the 5' ends of primers 2 and 4 had no detrimental effect on the quantity of specific DNA produced during the PcR. Analysis ofamplified cDNAs. Selected amplified cDNAs were subcloned into the plasmid vector pGEM-7Zf (Promega Biotech, Madison, WI), and subjected to nucleotide sequence analysis. Dideoxy sequencing was performed using the modified T7 phage DNA polymerase, Sequenase (United States Biochemicals, Cleveland, OH), according to the manufacturer's directions. Most PcR reaction products were directly exchanged into sterile water using Centricon 30 microconcentrators, and then digested with Nci 
Results
Nucleotide sequence analysis of GPIIIa from a plA2 homozygous individual. The nucleotide sequence of GPIIIa has been independently determined in three different laboratories (6) (7) (8) . Except for a single silent polymorphism in the codon for Va1355, no interlaboratory sequence differences exist within the coding region for the mature GPIIIa molecule. Since the PlAI phenotype is present in 98% of the population, it is likely that each of the three previously published sequences were derived from clones encoding the PlAI form of GPIIIa. To examine the amino terminal region of the PIA2 allele, we used the polymerase chain reaction to amplify a 366-bases region near the 5' end of platelet GPIIIa mRNA. Our amplification strategy used two sets of oligonucleotide primers, one nested internally to the first. The first 10 thermal cycles of the PcR amplified bases 4-412 -1,000-fold, and provided a sufficient quantity of GPIIIa-specific cDNA to permit more stringent conditions to be used in subsequent rounds. The remaining thermal cycles amplified bases 56-408 using an internally nested primer pair, which are graphically depicted in the top portion ofFig. 1 . This region encodes the first 103 amino acids of the mature GPIIIa protein, as well as a majority of the signal peptide. Using this protocol, we produced microgram amounts of the expected 366 bp cDNA from a number of individuals of known pIA phenotype. After subcloning into the plasmid pGEM-7Zf, the complete nucleotide sequence of bases 79-408 from one p1A2 homozygous individual was determined on both strands, and found to be identical to the three previously reported sequences for GPIIIa, except at base 196 (sequence numbering according to reference 6), which had a deoxycytosine (C) in place of a deoxythymidine (T). This single base change (shown in Fig. 2 ) results in substitution of a Pro for Leu at amino acid residue 33 of the mature GPIIIa molecule, and is likely to impart significant secondary structural differences.
Restriction enzyme analysis ofGPIIIa allotypes. Computer analysis of the GPIIIa sequence from bases 56-408 revealed that substitution of a C for a T at base 196 would create a recognition site for the restriction enzyme Nci I, which cleaves at 5'-CCGGG-3' but not 5'-CTGGG-3' sequences. To determine whether the T -o C substitution found in the p1A2 individual studied above was related to plA allotype, or merely represented an artifact generated in vitro during either the reverse transcriptase or Taq polymerase reactions, or an unrelated polymorphism of GPIIIa, platelet RNA was prepared from a total of 18 individuals of known plA phenotype, and then amplified using PcR to yield the same 366-bp product. As GPIIIa has been previously reported, and is printed on the right in normal size lettering for reference. The single base substitution of a C for a T at base 196 is indicated with an arrow. illustrated in Fig. 1 , Nci I should not be able to cleave the 366-bp cDNA from a plA' homozygous individual, whereas two fragments of 147 and 219 bp would be generated in a p1A2 homozygote. Fig. 3 shows that, as anticipated, the 366 bp cDNA amplified from plA' homozygous individuals was not cleaved by Nci I, whereas the predicted restriction fragments were obtained from PlA2/A2-derived cDNA. Serologically determined heterozygotes for the plA phenotype yielded both uncut 366 bp cDNA and the 219-and 147-bp restriction frag- cDNA derived from plAI homozygous individuals contain the sequence 5'-CTGGG-3', and is not cleaved by the enzyme, whereas cDNA amplified from plA2 homozygotes yielded two fragments of the expected sizes (see Fig. 1 ments, as expected. To date, we have successfully used this DNA typing procedure to predict the phenotype of 10 p1Al/A1, 5 p1A2/A2 and 3 p1A1/I individuals (P = 3.8 x 10-6).
Discussion
The plAI antigen commonly stimulates the alloimmune response associated with two syndromes, neonatal alloimmune thrombocytopenia and posttransfusion purpura. The plA1 and pjA2 antigenic determinants are carried on platelet membrane GPIIIa, and have been further localized to a 17-23-kD fragment of this molecule (5, 12) . Our ability to directly compare the amino acid sequence of GPIIIa derived from p1A2 versus PlAI individuals was made possible by: (a) the availability of the complete nucleotide sequence of GPIIIa cDNA (6-8) and (b) the application of gene amplification techniques to the study of phenotype-specific platelet mRNA sequences (9) . Based upon the published sequence of GPIIIa cDNA, we constructed oligonucleotide primer pairs that allowed us to enzymatically amplify a segment of the GPIIIa mRNA molecule that encodes the amino-terminal 103 amino acids of the mature glycoprotein. Examination of the nucleotide sequence derived from one p1A2 homozygous individual revealed a C T polymorphism at base 196. This single nucleotide substitution fortuitously results in the creation of a unique restriction enzyme cleavage site. Utilizing the ability of the enzyme Nci I to discriminate between these two polymorphic sequences, we analyzed the phenotypes of 17 additional individuals, and were able to demonstrate that the p1A2 form of GPIIIa mRNA contains the codon CCG (Pro33) in place of the CUG (Leu33 present in the plA' allele. As such, these findings represent the first molecular genetic characterization ofa polymorphism associated with a platelet-specific alloantigen system, and provide compelling evidence that the plA phenotype is a genetically determined, inherent property of the GPIIIa molecule, rather than a posttranslationally acquired epitope that becomes associated with this membrane glycoprotein.
Although the plA phenotype is clearly associated with a Leu/Pro polymorphism at amino acid 33, these studies do not directly address the issue of which amino acids form the actual antigenic epitope. There are a number of possible ways that this residue might participate in the formation of the plAI/pIA2 antigenic determinant. Leu/Pro33 could be physically located at the antigenic site, in which case this residue would constitute an integral part of the structure of the epitope. It is also possible that the presence (plA2) or absence (plAl) of Pro33 alters the secondary structure ofthe polypeptide chain, causing the actual antigenic determinant to be formed at another site. A third possibility, though less likely, 'is that the Leu/Pro33 polymorphism is simply coinherited with an as yet unidentified additional polymorphic region of GPIIIa. It should be possible to test these models by producing phenotype-specific synthetic peptides encompassing amino acid 33, which can be examined for their ability to directly bind anti-PlAl or anti-PlA2 antibodies, or to inhibit the binding of these alloantibodies to platelets of the appropriate phenotype. Similarly, antipeptide antibodies can be produced and examined for their ability to react selectively with platelets of known plAI and p1A2 phenotype. One potential obstacle in using peptides to examine plA epitopes is that they are often incapable ofmimicking complex conformationally dependent determinants. Thus, an alternative strategy might involve the production of cell lines trans-fected with GPIIIa molecules differing only at amino acid 33. Serological evaluation of such "phenotype-specific" transfectants may ultimately be more useful in defining the molecular nature of these alloantigenic determinants. In any event, it is clear that more work needs to be done in order to localize the epitopes on the native GPIIIa molecule to which PlA-specific antibodies bind.
Studies are currently in progress to determine whether other regions of the GPIIIa molecule contain polymorphisms that correlate with pIA phenotype. Zimrin et al. (7) 
